Skip to main content
XTNT logo

XTNT · Xtant Medical Holdings, Inc. · Documents

Track XTNT — free
$0.26 -0.01 (-4.20%) Play latest call Q2 2026 earnings call transcript
Market Cap
$38.12M
Shares
140.29M
Volume · Nov 13 181.75K Avg daily vol (3M) 1.67M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $133.93M up 14.2% 10-K filed Mar 31, 2026 Quarterly report New Ended Sep 30, 2026 Revenue $24.29M down 27.0% 10-Q filed Nov 16, 2026 Latest results New Strategic review follows second consecutive quarterly guidance miss 8-K filed Nov 16, 2026 Earnings call Q2 2026 earnings call Held Aug 11, 2026
2026
Nov 16
Quarterly report 10-Q Ended Sep 30
Material weakness persists amid debt covenant pressure

Xtant Medical Holdings reported ineffective disclosure controls due to an inventory valuation material weakness as of September 30, 2026. It lost $16.1 million and used $10.3 million in operating activities during nine months, required covenant amendments, and withdrew 2026 guidance.

Revenue $24.29M ▼ 27.0% Net loss $3.56M Diluted EPS -$0.03
Read from the MD&A section
7 source passages
I have reviewed this quarterly report on Form 10-Q of Xtant Medical Holdings, Inc.; Based upon that evaluation, and as a result of the material weakness in our internal control over financial reporting discussed below, our principal executive officer and principal financial officer concluded that as of September 30, 2026, our disclosure controls and procedures were not effective. More specifically, our controls surrounding our evaluation of inventory net realizable value were insufficient and did not operate at an appropriate level of precision. For the nine months ended September 30, 2026, we had a net loss of $16.1 million and used $10.3 million of cash in operating activities. In March 2026, we entered into the Amendment No. 4s with MidCap. In August 2026, we entered into the Amendment No. 5s, which eliminated the requirement for that quarter and set new minimum net revenue amounts. We have withdrawn our full-year 2026 financial guidance and are not providing revised guidance during the review, which may reduce the information available to investors. Open the document at this passage
Nov 16
Current report 8-K
Strategic review follows second consecutive quarterly guidance miss

Xtant Medical launched a board-led strategic review after missing guidance for a second consecutive quarter. Third-quarter revenue was $24.3 million, net loss was $3.6 million, adjusted EBITDA was a loss of $1.5 million, and previously issued full-year 2026 guidance will not be achieved.

Financial results
6 source passages
Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable,” said Stavros Vizirgianakis, Chairman of the Board. Total revenue was $24.3 million for the third quarter of 2026, compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. Net loss for the third quarter of 2026 was $3.6 million, or $0.03 per share, compared to net income of $1.3 million, or $0.01 per diluted share, for the third quarter of 2025. Adjusted EBITDA, a non-GAAP measure, was a loss of $1.5 million for the third quarter of 2026, compared to adjusted EBITDA of $4.5 million for the third quarter of 2025. Based on year-to-date performance, the Company no longer expects to achieve its previously issued full-year 2026 guidance. Open the document at this passage
Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $23.03M ▼ 35.0% Net loss $9.41M Diluted EPS -$0.07
May 13
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $20.88M ▼ 36.5% Net loss $3.09M Diluted EPS -$0.02
Mar 31
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $133.93M ▲ 14.2% Net income $4.97M Diluted EPS $0.03
Mar 2
Current report 8-K
Other events AI summary on its way
Jan 16
Current report 8-K Events of Jan 15
Other events AI summary on its way
2025
Mar 6
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $117.27M ▲ 28.4% Net loss $16.45M Diluted EPS -$0.12
2024
Showing 1–50 of 153 documents
Key facts CIK 1453593 CUSIP 98420P308 13F (30d) 29 filings 23 filers Visit website Investor relations